Royalty Pharma: PTC Therapeutics Exercised Option to Sell Half of Retained Royalties on Roche's Evrysdi to Co's Unit for About $242 Mln Upfront
ptc therapeutics行使出售羅氏Evrysdi保留版稅一半的選擇權,以約2.42億美元的價格賣給了該公司旗下的royalty pharma。
Royalty Pharma: PTC Therapeutics Exercised Option to Sell Half of Retained Royalties on Roche's Evrysdi to Co's Unit for About $242 Mln Upfront
ptc therapeutics行使出售羅氏Evrysdi保留版稅一半的選擇權,以約2.42億美元的價格賣給了該公司旗下的royalty pharma。
譯文內容由第三人軟體翻譯。